/BFFTF
BFFTF Stock - Biofrontera AG
Healthcare|Drug Manufacturers - Specialty & GenericOTC
$0.33-95.24%
$6.60 (-95.24%) • May 30
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.10
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.96
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.36
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BFFTF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.33 – $0.33
TARGET (TP)$0.38
STOP LOSS$0.30
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.59
52W High$22.68
52W Low$0.33
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $34.07M | $28.67M | $24.10M | $18.85M | $26.18M |
| Gross Profit | $16.63M | $13.49M | $11.36M | $9.78M | $13.77M |
| Gross Margin | 48.8% | 47.0% | 47.1% | 51.9% | 52.6% |
| Operating Income | $-22,677,000 | $-22,381,000 | $-25,851,000 | $-8,334,000 | $-14,922,000 |
| Net Income | $-20,131,000 | $-640,000 | $-37,713,000 | $-10,987,000 | $-10,982,000 |
| Net Margin | -59.1% | -2.2% | -156.5% | -58.3% | -41.9% |
| EPS | $-13.02 | $-0.61 | $-44.10 | $-18.94 | $-18.09 |
Company Overview
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BFFTFBeat Rate
54%
Last 13 quarters
Avg Surprise
-645.7%
EPS vs Estimate
Beats / Misses
7/6
Last 12 quarters
Latest EPS
$-0.98
Q4 2024
EPS Surprise History
Q1 23
-529.7%
$-2.09vs$-0.33
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 26, 2024 | — | $-0.98 | — | — |
Q3 2024 | Aug 31, 2024 | — | $-0.05 | — | — |
Q2 2024 | Apr 30, 2024 | — | $-2.88 | — | — |
Q1 2024 | Mar 15, 2024 | — | $1.65 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-4.64 | — | — |
Q3 2023 | Aug 11, 2023 | — | $-7.23 | — | — |
Q2 2023 | May 12, 2023 | — | $-5.60 | — | — |
Q1 2023 | Mar 13, 2023 | $-0.33 | $-2.09 | -529.7% | ✗ MISS |
Q4 2022 | Nov 23, 2022 | $-1.52 | $-2.26 | -48.9% | ✗ MISS |
Q3 2022 | Aug 18, 2022 | $-1.19 | $7.51 | +731.4% | ✓ BEAT |
Q2 2022 | Apr 30, 2022 | $-0.09 | $0.90 | +1100.0% | ✓ BEAT |
Q2 2022 | Apr 9, 2022 | $-0.26 | $-25.89 | -9686.6% | ✗ MISS |
Q4 2021 | Nov 17, 2021 | $-0.19 | $-0.10 | +47.4% | ✓ BEAT |
Q3 2021 | Aug 19, 2021 | $-0.11 | $-0.07 | +36.4% | ✓ BEAT |
Q2 2021 | May 11, 2021 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q2 2021 | Apr 12, 2021 | $-0.23 | $-0.47 | -100.0% | ✗ MISS |
Q4 2020 | Nov 11, 2020 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q3 2020 | Jul 14, 2020 | $0.01 | $0.02 | +199.9% | ✓ BEAT |
Q2 2020 | May 19, 2020 | $-0.11 | $-0.14 | -27.3% | ✗ MISS |
Q2 2020 | Apr 20, 2020 | $-0.04 | $-0.10 | -150.0% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about BFFTF
What is BFFTF's current stock price?
Biofrontera AG (BFFTF) is currently trading at $0.33 per share. The stock has moved -95.24% today.
What is the analyst price target for BFFTF?
No analyst price targets are currently available for this stock.
What sector is Biofrontera AG in?
Biofrontera AG operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.
What is BFFTF's market cap?
Biofrontera AG has a market capitalization of $0.02 billion, making it a small-cap company.
Does BFFTF pay dividends?
No, Biofrontera AG does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATHJF
Antisense Therapeutics Limited
$0.01
Mkt Cap: $0.0B
GRAMF
TPCO Holding Corp.
$0.16
Mkt Cap: $0.0B
HMPSF
The Hempshire Group, Inc.
$0.19
Mkt Cap: $0.0B
NXTTF
Lifeist Wellness Inc.
$0.04
Mkt Cap: $0.0B
PCHM
PharmChem, Inc.
$3.75
Mkt Cap: $0.0B
RAMMF
RAMM Pharma Corp.
$0.06
Mkt Cap: $0.0B
RWBYF
Red White & Bloom Brands Inc.
$0.03
Mkt Cap: $0.0B
SRNEQ
Sorrento Therapeutics, Inc.
$0.03
Mkt Cap: $0.0B
TGPHF
Together Pharma Ltd
$0.09
Mkt Cap: $0.0B
VNNYF
Vinergy Capital Inc.
$0.15
Mkt Cap: $0.0B
Explore stocks similar to BFFTF for comparison